# The Paradox of Potency: Why Street Drugs Keep Getting Stronger and Cheaper
Five decades of drug enforcement have produced the opposite of their intended effect. Illicit drugs are now cheaper and more potent than at any point in modern history, creating a crisis that traditional approaches have failed to address.
In Baltimore, the epicenter of America's opioid epidemic, this reality plays out in raw detail. The drugs circulating there bear little resemblance to heroin from decades past. Today's street supply contains fentanyl, xylazine, and other synthetic substances that pack lethal doses into tiny quantities. A single grain the size of a salt crystal can kill. Prices have collapsed. Dealers now compete on purity and potency rather than availability.
This shift reflects fundamental changes in drug chemistry and supply chains. Synthetic opioids require no poppy fields, no agricultural infrastructure. They come from chemical laboratories, often overseas, compressed into powder that travels easily across borders. Carfentanil, a veterinary anesthetic 100 times stronger than fentanyl, now appears in street drugs with disturbing frequency. Xylazine, a sedative used in animals, has become a common adulterant because it extends the high and costs dealers almost nothing.
The economics are relentless. Prohibition created high prices that incentivized innovation. Chemists responded by developing substances that deliver more effect per molecule, per dollar, per milligram. Each new synthetic drug is designed to evade law enforcement detection and deliver a more intense high than its predecessor. Markets reward efficiency, whether legal or otherwise.
This dynamic contradicts the foundational logic of drug policy. Enforcement was supposed to reduce supply and raise prices, making drugs unaffordable for users. Instead, enforcement increased prices just enough to justify innovation while disrupting traditional supply chains. Cartels adapted faster than policy shifted.
The human toll reflects this miscalculation. Overdose deaths in Baltimore routinely spike as new drugs enter the supply. Users often have no idea what they are consuming. A dose that produced a manageable high yesterday produces death today. Naloxone, the overdose reversal medication, sometimes fails to work against the newest synthetic combinations.
Harm reduction advocates point to the evidence: supervised consumption sites in other countries reduce overdose deaths. Drug testing services allow users to know exactly what they are taking. Medication-assisted treatment, combining behavioral therapy with medications like buprenorphine or methadone, saves lives. Addiction medicine specialists like Dr. Alexander Walley at Boston University have documented that these approaches reduce both use and criminal justice involvement.
Yet Baltimore's experience shows that no single intervention works when the drug supply itself continues to evolve. Fentanyl-focused interventions become obsolete as xylazine spreads. Naloxone becomes less effective against new synthetic combinations. Users need multiple rescue medications and repeated treatment attempts.
The ruthless efficiency of synthetic drugs exposes a gap between policy and chemistry. Enforcement can disrupt supply chains temporarily but cannot address the underlying incentive structure that rewards potency and cost-effectiveness. Until that incentive structure changes, innovation in illicit drug chemistry will outpace law enforcement response. Baltimore's streets document this failure in overdose statistics and empty storefronts where users gather to survive another day.